TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1432467
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (5 mg/kg body weight/day) for 2 weeks
Study: 1432467
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in multivitamin syrup for 2 weeks
Study: 28135389
Drug: Weekly telephone
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly telephone intervention problem solving (TIPS)
Study: 23966217
Drug: Systemic steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic steroid (S)
Study: 19126319
Drug: Dilapan-S™ and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilapan-S™ and misoprostol combination
Study: 17606053
Drug: 1 injection
Normalized name: vitamin K1 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 injection of injectable mixed subtype collagenase
Study: 17606053
Drug: 3 injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 injections of injectable mixed subtype collagenase
Study: 17606053
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with injectable mixed subtype collagenase
Study: 15478484
Drug: 5% sodium
Normalized name: Dextrose 5% and 0.45% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% sodium fluoride (NaF) bioerodible gel
Study: 15478484
Drug: Control gel
Normalized name: SALICYLIC ACID 20 mg in 1 mL TOPICAL GEL [Walgreens Acne Control Gel]
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control gel (no treatment)
Study: 8018000
Drug: Aspirin (combined)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (combined)
Study: 29025837
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12 at a dose of 10^9 colony-forming units, orally, once daily for 6 months.
Study: 29025837
Drug: Placebo, identically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, identically appearing, orally, once daily for 6 months.
Study: 22164492
Drug: Capsule Xinganbao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule Xinganbao
Study: 12713211
Drug: After-school intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: After-school intervention focused on increasing physical activity and healthy eating, conducted twice a week for 12 weeks
Study: 11095423
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg PEG‐OB weekly subcutaneous injections
Study: 1319187
Drug: Succinylcholine 1
Normalized name: Succinylcholine 124 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 1 mg/kg with thiopental sodium, fentanyl, and midazolam, maintained with 70% nitrous oxide in oxygen
Study: 2934708
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (4-6 mg/mg/day) introduced at 3rd month after transplantation
Study: 2934708
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (prednisone, azathioprine, and antilymphocyte serum)
Study: 23059149
Drug: Wake therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wake therapy with bright light therapy and sleep time stabilization
Study: 18420531
Drug: Pegloticase 12
Normalized name: Pegloticase
DrugBank: Pegloticase (DB09208)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegloticase 12 mg every 4 weeks
Study: 18420531
Drug: Pegloticase 4
Normalized name: Pegloticase
DrugBank: Pegloticase (DB09208)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegloticase 4 mg every 2 weeks
Study: 18759308
Drug: Infusion-day adverse
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion-day adverse events
Study: 18759308
Drug: Antipegloticase antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipegloticase antibody presence
Study: 12136446
Drug: Manualized Psychodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manualized Psychodynamic Therapy
Study: 7486839
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg added caffeine
Study: 31215092
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (escalating daily doses from 400 to 4800 IU)
Study: 18344024
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (three cycles of 3-weekly FEC(100) then three cycles of 3-weekly Doc 100 mg/m(2))
Study: 18344024
Drug: Dose-dense treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense treatment (four 10- to 11-day cycles of FEC(75) then four 2-weekly cycles of Doc 75 mg/m(2))
Study: 18344024
Drug: Dose-dense treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense treatment (Doc given after FEC)
Study: 23948349
Drug: Dose-dense treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense treatment
Study: 16978370
Drug: RSGMET (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSGMET (4 mg rosiglitazone / 500 mg metformin, escalated to 8 mg/2 g)
Study: 16978370
Drug: MET (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: MET (500 mg, escalated to 3 g)
Study: 15325604
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with anal fissure before treatment
Study: 11843992
Drug: Ciprofloxacin (CIP)
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin (CIP) oral suspension (250 mg/5 mL twice daily)
Study: 11843992
Drug: Trimethoprim/sulfamethoxazole (TMP/SMX)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim/sulfamethoxazole (TMP/SMX) oral suspension (160/800 mg/20 mL twice daily)
Study: 9763553
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous Ig (IVIg) (1 g/kg/d for 2 days)
Study: 9763553
Drug: Long-term IVIg
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term IVIg therapy (repeated single infusions every 21 days)
Study: 3290034
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg intravenous glucagon (50 patients)
Study: 7679164
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg, three times daily for 3 days)
Study: 28468607
Drug: Group LIA
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group LIA (Local Infiltration Analgesia) with 30 mL saline, ropivacaine 2 mg/mL (300 mg), ketorolac 30 mg, adrenaline 0.5 mg
Study: 28468607
Drug: Group FNB
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group FNB (Femoral Nerve Block) with 30 mL ropivacaine 7.5 mg/mL (225 mg) and 151.5 mL saline
Study: 26073387
Drug: ETC-1002 60
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ETC-1002 60 mg daily (increased to 120 mg, 180 mg, and 240 mg at 2-week intervals)
Study: 24173676
Drug: 25 ml
Normalized name: ethanol 6.025 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 ml 0.5% levobupivacaine plus 4 mg dexamethasone (group 1)
Study: 24173676
Drug: 25 ml
Normalized name: ethanol 6.025 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 ml 0.5% levobupivacaine plus 1 ml saline (group 2)
Study: 22679695
Drug: Intravitreal pegaptanib
Normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravitreal pegaptanib (0.3 mg) or bevacizumab (0.625 mg/0.025 ml) with conventional diode laser photocoagulation (Group A)
Study: 22679695
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy combined with cryotherapy (Group B)
Study: 19041224
Drug: Coenzyme Q(10)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coenzyme Q(10) (50 mg/d), vitamin E (50 mg/d), and selenium (48 mug/d)
Study: 8633396
Drug: Self-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of the International Prostate Symptom Score (IPSS)
Study: 8633396
Drug: Physician administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physician administration of the International Prostate Symptom Score (IPSS)
Study: 19915217
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin (2000 mg per day)
Study: 19915217
Drug: Ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10 mg per day)
Study: 9253326
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE; 250 mg, i.m., every 21 days)
Study: 9253326
Drug: Single s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single s.c. implantation of 1200 mg crystalline testosterone (TPEL)
Study: 31225647
Drug: BoNT‐A plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT‐A plus occupational therapy
Study: 23787544
Drug: Paricalcitol 2
Normalized name: PARICALCITOL 2MCG CAP,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paricalcitol 2 μg/day
Study: 16948806
Drug: Tapering down
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering down omeprazole for three weeks
Study: 16948806
Drug: Constant dosage
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant dosage of omeprazole for three weeks
Study: 16948806
Drug: Overall discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall discontinuation of PPIs
Study: 10899492
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA), 50 mg/d for 3 months
Study: 8177098
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (20 micrograms ethinyl estradiol and 150 micrograms desogestrel) for 6 months
Study: 3653128
Drug: Oestrogen therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen therapy (polyestradiol phosphate 80 mg i.m. per month + 150 micrograms ethinylestradiol p.o. per day)
Study: 27940956
Drug: Liraglutide (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (1.8 mg subcutaneously before intervention, followed by 0.6 mg for 2 days, 1.2 mg for 2 days, and 1.8 mg for 3 days)
Study: 26575873
Drug: Aminophylline 1
Normalized name: aminophylline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline 1 mg/kg, once every 8 hours
Study: 26575873
Drug: Aminophylline 2
Normalized name: aminophylline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline 2 mg/kg, once every 8 hours
Study: 21504340
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of oral micronized progesterone capsules (Utrogestan 3 x 100 mg) and vaginal progesterone gel (Crinone 8%, 90 mg daily)
Study: 21504340
Drug: Progesterone monotherapy
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone monotherapy (vaginal progesterone gel, Crinone 8%, 90 mg daily)
Study: 21504340
Drug: Progesterone monotherapy
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone monotherapy
Study: 18425621
Drug: Thalidomide (THL)
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide (THL) in combination with riluzole
Study: 16495259
Drug: Artesunate suppositories
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate suppositories (8 to 16 mg/kg at 0 and 12 h, then daily)
Study: 16495259
Drug: Intramuscular artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular artemether (3.2 mg/kg at 0 h, then 1.6 mg/kg daily)
Study: 2317442
Drug: Inderal LA
Normalized name: Inderal LA
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inderal LA 80 mg
Study: 2317442
Drug: Inderal LA
Normalized name: Inderal LA
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inderal LA 160 mg
Study: 2317442
Drug: Inderal LA
Normalized name: Inderal LA
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inderal LA 320 mg
Study: 31137994
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with LP Nd:YAG laser and 10% KOH application
Study: 31137994
Drug: LP Nd:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: LP Nd:YAG laser therapy only
Study: 25869983
Drug: Modified osteotomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified osteotomy design (angled oblique buccal bone cut)
Study: 10648268
Drug: Vitamin cocktail
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin cocktail containing 272 mg vitamin C, 31 mg all‐rac‐alpha‐tocopheryl acetate, and 400 microg folic acid
Study: 9144686
Drug: Paclitaxel 200
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m2 intravenously over 3 hours for eight cycles (6 months)
Study: 9144686
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with oral cyclophosphamide (100 mg/m2/d days 1 through 14), intravenous methotrexate (40 mg/m2 days 1 and 8), intravenous 5-fluorouracil (600 mg/m2 days 1 and 8), and oral prednisolone (40 mg/m2/d days 1 through 14) for six cycles (6 months)
Study: 8129554
Drug: Hydroquinidine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroquinidine (600 mg per 24 hours)
Study: 8129554
Drug: Quinidine (1100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (1100 mg)
Study: 24702733
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with metformin
Study: 24702733
Drug: Metformin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin with rosiglitazone
Study: 24702733
Drug: Metformin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin with intensive lifestyle intervention
Study: 20446889
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D intake (average daily intake 144.8 IU, SD 84.6)
Study: 20446889
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake (average daily intake 966.4 mg, SD 273.7)
Study: 18611063
Drug: Intravenous lanthanum
Normalized name: lanthanum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lanthanum chloride
Study: 18611063
Drug: Oral lanthanum
Normalized name: lanthanum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lanthanum carbonate (3000 mg/day)
Study: 18611063
Drug: Oral lanthanum
Normalized name: lanthanum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lanthanum carbonate
Study: 12851624
Drug: AMP579 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMP579 (60 mcg/kg)
Study: 12851624
Drug: AMP579 (other
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMP579 (other doses)
Study: 12851624
Drug: AMP579 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMP579 (all doses)
Study: 11601221
Drug: Antilymphocyte globulin
Normalized name: antilymphocyte immunoglobulin
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antilymphocyte globulin (ALG) combined with cyclosporine A (CsA) - Intensive immunosuppressive therapy (IIST)
Study: 11601221
Drug: Antilymphocyte globulin
Normalized name: antilymphocyte immunoglobulin
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antilymphocyte globulin (ALG) alone - Non-intensive immunosuppressive therapy (NIIST)
Study: 8678273
Drug: Pressure-controlled mechanical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure-controlled mechanical ventilation with PEEP and permissive hypercapnia, body position changes, inhalation of nitric oxide.
Study: 8678273
Drug: Traditional standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional standard treatment (not specified in detail).
Study: 1411294
Drug: Bismuth compound
Normalized name: Bismuth compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth compound (120 mg four times daily)
Study: 24680768
Drug: Tacrolimus administered
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus administered via site-specific radiolabeled delivery capsule (1 mg in 2 mg/mL solution)
Study: 24680768
Drug: Tacrolimus administered
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus administered via site-specific radiolabeled delivery capsule
Study: 20199989
Drug: Control (antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (antiretroviral treatment only)
Study: 18279690
Drug: Three gels
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three gels containing different doses of N-9
Study: 18279690
Drug: Three different
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three different formulations containing the same dose of N-9
Study: 18279690
Drug: Different formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different formulations and doses of spermicides containing N-9
Study: 16167911
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of levobupivacaine
Study: 16167911
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of racemic bupivacaine
Study: 8904258
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg lidocaine (LD)
Study: 8904258
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg meperidine (MP)
Study: 8904258
Drug: 25 mu
Normalized name: OCTINOXATE 0.07 g in 1 g / ZINC OXIDE 0.084 g in 1 g TOPICAL CREAM [CY BB Facial Hidratante con Color FPS 25 Multibeneficios]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mu g fentanyl (FN)
Study: 6280796
Drug: New designed
Approvals — FDA: no, EMA: no, PMDA: no
Description: New designed intermittent polychemotherapy-schedule (alternating cyclophosphamid + CCNU + MTX, then cyclophosphamid + adriamycin + vincristin, then ifosfamid + VP‐16) followed by radiation therapy
Study: 23206459
Drug: Oral prolonged-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prolonged-release oxycodone/naloxone (OXN PR)
Study: 11857049
Drug: Flaxseed supplementation
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed supplementation (1.3 g/100 g ground flaxseed and 5 g/100 g flaxseed oil)
Study: 10439881
Drug: Low-dose glucose-insulin-potassium
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose glucose-insulin-potassium (GIK)
Study: 25199856
Drug: Dietary NO3(‐)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary NO3(‐) intake (140 mL of concentrated beetroot juice containing 11.2 mmol of NO3(‐))
Study: 25199856
Drug: Placebo (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (140 mL of beetroot juice devoid of NO3(‐))
Study: 23726325
Drug: Oscillating-rotating electric
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oscillating-rotating electric toothbrush with a specially designed orthodontic brush head (Oral-B Triumph, OD17)
Study: 17146025
Drug: Health plan-based
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Health plan-based lifestyle intervention (bimonthly group meetings, quarterly coaching telephone calls, and weekly self-monitoring)
Study: 12750437
Drug: Oral valacyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral valacyclovir administration
Study: 12750437
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir administration
Study: 3909500
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 300 mg daily for 2 weeks
Study: 3909500
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 600 mg daily for 2 weeks
Study: 3909500
Drug: Atherogenic diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atherogenic diet with 100 mg vitamin E daily
Study: 29365382
Drug: Systemic glucocorticoids
Normalized name: Glucocorticoids, Systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic glucocorticoids combined with inhaled steroid (Budesonide suspension 1.0 mg for inhalation, oxygen-driven atomizing inhalation, every 30 minutes, 2 times in a row, then every 12 hours)
Study: 29365382
Drug: Systemic glucocorticoids
Normalized name: Glucocorticoids, Systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic glucocorticoids (Dexamethasone injection 0.3‐0.5 mg/kg for 1‐3 days)
Study: 25359002
Drug: Tornado program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tornado program (accelerated-track diagnosis and treatment planning, psychoeducation, pharmacological treatment by primary care physicians)
Study: 22616062
Drug: Ceramic material
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceramic material titanium niobium oxynitride ([Ti,Nb]ON) with plasma‐chemical oxidation treatment
Study: 20736206
Drug: Overlapping drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overlapping drug-eluting stents (DES)
Study: 11986913
Drug: Regular nimodipine
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regular nimodipine 30 mg every 6 h
Study: 11986913
Drug: Nimodipine AP
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine AP 120 mg every 24 h